Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

March 12, 2019

Study Completion Date

March 12, 2019

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)

OTHER

Normal saline

Normal saline is 0.9% sodium chloride

BIOLOGICAL

PfSPZ Challenge (for CHMI)

Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54

Trial Locations (1)

Unknown

Baney Clinical Research Center, Santiago de Baney

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ifakara Health Institute

OTHER

collaborator

Swiss Tropical & Public Health Institute

OTHER

collaborator

Government of Equatorial Guinea

OTHER_GOV

collaborator

Noble Oil Services

INDUSTRY

collaborator

Marathon Oil Corporation

INDUSTRY

collaborator

Atlantic Methanol Production Company

UNKNOWN

collaborator

Equatorial Guinea (EG) liquefied natural gas (LNG)

UNKNOWN

lead

Sanaria Inc.

INDUSTRY

NCT03590340 - Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea | Biotech Hunter | Biotech Hunter